Literature DB >> 7510240

The human OX40 homolog: cDNA structure, expression and chromosomal assignment of the ACT35 antigen.

U Latza1, H Dürkop, S Schnittger, J Ringeling, F Eitelbach, M Hummel, C Fonatsch, H Stein.   

Abstract

Tissue distribution and expression on mitogen and virally stimulated lymphocytes render the ACT35 molecule a human lymphocyte activation antigen which as yet could not be clustered. Expression cloning of the ACT35 antigen from a pCDM8 library of the HUT-102 cell line revealed strong homology of the cDNA and its encoded protein sequence with the formerly described rat OX40 antigen. The 1.4-kb nucleotide sequence and the deduced 277-amino acid sequence of the single transmembrane protein were 65% and 63% identical, in human and in rat, respectively. Conservation included one N-linked glycosylation site and one protein kinase C phosphorylation site. When expressed in COS-1 cells, the cDNA presented properties comparable to the native ACT35 antigen and the rat OX40 molecule (relative molecular mass 48,000). Thus, the ACT35 protein corresponds to the hitherto unknown human OX40 antigen and is, therefore, another member of the tumor necrosis factor/nerve growth factor receptor (TNFR/NGFR) family. After applying fluorescence in situ hybridization, the human ACT35/OX40 gene could be mapped to chromosome band 1p36 and is, thus, linked to the genes for TNFR II and CD30.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7510240     DOI: 10.1002/eji.1830240329

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  28 in total

1.  Essential role of OX40L on B cells in persistent alloantibody production following repeated alloimmunizations.

Authors:  Hiroshi Kato; Hidefumi Kojima; Naoto Ishii; Hidenori Hase; Yutaka Imai; Takashi Fujibayashi; Kazuo Sugamura; Testuji Kobata
Journal:  J Clin Immunol       Date:  2004-05       Impact factor: 8.317

2.  OX40 stimulation by gp34/OX40 ligand enhances productive human immunodeficiency virus type 1 infection.

Authors:  Y Takahashi; Y Tanaka; A Yamashita; Y Koyanagi; M Nakamura; N Yamamoto
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

3.  Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells.

Authors:  S M Lens; P A Baars; B Hooibrink; M H van Oers; R A van Lier
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

4.  OX40 signaling renders adult T-cell leukemia cells resistant to Fas-induced apoptosis.

Authors:  Akane Kunitomi; Toshiyuki Hori; Michiyuki Maeda; Takashi Uchiyama
Journal:  Int J Hematol       Date:  2002-10       Impact factor: 2.490

Review 5.  Bone marrow transplantation and approaches to avoid graft-versus-host disease (GVHD).

Authors:  Bruce R Blazar; William J Murphy
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2005-09-29       Impact factor: 6.237

6.  Sequential CD134-CXCR4 interactions in feline immunodeficiency virus (FIV): soluble CD134 activates FIV Env for CXCR4-dependent entry and reveals a cryptic neutralization epitope.

Authors:  Aymeric de Parseval; Chris K Grant; K Jagannadha Sastry; John H Elder
Journal:  J Virol       Date:  2006-03       Impact factor: 5.103

7.  Pimecrolimus inhibits up-regulation of OX40 and synthesis of inflammatory cytokines upon secondary T cell activation by allogeneic dendritic cells.

Authors:  F S Kalthoff; J Chung; A Stuetz
Journal:  Clin Exp Immunol       Date:  2002-10       Impact factor: 4.330

Review 8.  Function of tumor necrosis factor receptor family members on regulatory T-cells.

Authors:  Robert H Arch
Journal:  Immunol Res       Date:  2005       Impact factor: 2.829

9.  Mapping of Receptor Binding Interactions with the FIV surface Glycoprotein (SU); Implications Regarding Immune surveillance and cellular Targets of Infection.

Authors:  Qiong-Ying Hu; Elizabeth Fink; John H Elder
Journal:  Retrovirology (Auckl)       Date:  2012-07-11

10.  Feline immunodeficiency virus targets activated CD4+ T cells by using CD134 as a binding receptor.

Authors:  Aymeric de Parseval; Udayan Chatterji; Peiqing Sun; John H Elder
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.